CTOs on the Move

Calliditas

www.calliditas.com

 
Calliditas is a specialty pharmaceutical company developing high value products for patients with significant unmet medical needs. With a highly experienced, dynamic management team, Calliditas draws on its extensive experience of pharmaceutical development and marketing to efficiently identify and progress valuable and de-risked products.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Lars Stubberud
Head of Technical Operations Profile

Similar Companies

RHEI Pharmaceuticals

RHEI Pharmaceuticals is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Savage Laboratories

Savage Laboratories is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthon Pharmaceuticals Inc

Synthon Pharmaceuticals Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carondelet Medical Group

Carondelet Medical GroupPatient Centered Care, Experienced Medical ExcellenceThe Carondelet team is here to provide exceptional, patient-centered medical care for the entire family. From routine check-ups to chronic disease management to healing from a...

Momenta Pharmaceuticals

Momenta is a biotechnology company with a product pipeline of both complex mixture generic and novel drugs. Our complex mixture generics and follow-on biologics effort is focused on building a thorough understanding of the structure-process-activity of complex mixture drugs to develop generic versions of marketed products. While we use a similar analytical and development approach across all of our product candidates, we tailor that approach for each specific product candidate. Our first objective is to apply our core analytical technology to thoroughly characterize the structure of the marketed product. By defining the chemical composition of multiple batches of a marketed product, we are able to develop an equivalence window which captures the inherent variability of the innovator`s manufacturing process. Using this information, we then build an extensive understanding of the structure-process relationship to design and control our manufacturing process to manufacture reproducibly an equivalent version of the marketed product. Where necessary, and as required by the U.S. Food and Drug Administration, or FDA, we will supplement an application with additional supportive structure-activity data (e.g., immunogenicity, pharmacodynamics). Our goal is to obtain FDA approval for and commercialize generic or follow-on versions of complex mixture products, thereby providing high quality, safe and affordable medicines to patients in need.